In heart failure, cardiac specific beta-1 blockade is protective and there is some evidence that cardiac selective beta blockers are useful in reducing cardiotoxic events in breast cancer patients treated with anthracyclines and the anti-HER2/neu monoclonal antibody trastuzumab30,31. Here, ERBB2 is linked to heart failure.